TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06636175
Drug: 64Cu-LLP2A
Normalized name: 64Cu-dotatate
DrugBank: Copper oxodotreotide Cu-64 (DB15873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)
Study: NCT05151692
Drug: Nipocalimab
Normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nipocalimab will be administered as an IV infusion.
Study: NCT05439993
Drug: Tepotinib plus paclitaxel
Normalized name: Tepotinib
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80mg/m2 on D1, 8, 15 tepotinib 250mg or 500mg daily on D1-28 Q 4weeks
Study: NCT05523609
Drug: Letrozole 2.5mg
Normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 patients will receive Letrozole only for 12 weeks
Study: NCT05523609
Drug: Letrozole + vitamin D3 and calcium
Normalized name: vitamin D3
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 patients will receive Letrozole in addition to 2000 IU vitamin D3 per day for 12 weeks.
Study: NCT05664659
Drug: Oxytocin + misoprostol
Normalized name: Misoprostol
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 micrograms misoprostol rectally 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution
Study: NCT05664659
Drug: Carbetocin
Normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms carbetocin
Study: NCT05528653
Drug: Descovy
Normalized name: Descovy
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HIV infection pre-exposure prophylaxis
Study: NCT06075147
Drug: Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Following the manner of observational study, no intervention will be provided in the study. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and follows approved clinical guidelines.
Study: NCT05282108
Drug: Carcemia
Normalized name: CARCINIA MANGOSTANA
DrugBank: Mango (DB10657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic Imatinib
Study: NCT05282108
Drug: Glivec
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib
Study: NCT06074588
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2 of docetaxel by IV Infusion
Study: NCT06074588
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m\^2 of pemetrexed by IV infusion
Study: NCT04609592
Drug: Lutathera
Normalized name: Lutathera
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 administrations of 7.4 gigabecquerel (GBq) (200 mCi) 177Lu Dotatate +/ 10% at the date and time of infusion, accumulative dose of 29.6 GBq (800 mCi). T
Study: NCT04609592
Drug: Gallium 68 Dotatate
Normalized name: Gallium 68 dotatate
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care, 2 Megabecquerel (MBq)/kg (0.054 mCi/kg) up to 200 MBq (5.4 mCi)
Study: NCT05651711
Drug: Rocatinlimab
Normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocatinlimab will be administered through a subcutaneous (SC) injection.
Study: NCT06081244
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg/kg twice on Days 1 and 8 of a continuous 21-day treatment cycle
Study: NCT06081244
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg every 3 weeks (q3w)
Study: NCT04168203
Drug: Apixaban 2.5 MG
Normalized name: apixaban 2.5 MG
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: apixaban 2.5 mg orally twice daily for a duration of 12 months
Study: NCT05097651
Drug: Cannabidiol oral solution
Normalized name: cannabidiol Oral Solution
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol 100mg/mL in a sesame seed oil, strawberry flavored solution, taken orally at bedtime in self-titrated dose between 50mg and 600mg. Once a dose that results in relief of symptoms is reached, it will remain as the maintenance dose, not to exceed 600mg.
Study: NCT05097651
Drug: Inert sesame seed oil
DrugBank: Sesame seed (DB10566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be identical strawberry flavored sesame seed oil-based solution without CBD.
Study: NCT05484505
Drug: Nicotine patch, Nicotine gums
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine patch 21mg, 12 weeks post quit date and nicotine chewing gums 4mg for 12 weeks post quit date~* 14 mg: Next 4 weeks~* 7 mg: Last 4 weeks
Study: NCT05484505
Drug: Nicotine Patch: Preloading for 4 weeks
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Patch: Preloading for 4 weeks - 21 mg: 4 weeks before quit date
Study: NCT04916353
Drug: hypertonic dextrose water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% hypertonic dextrose water injection for chronic shoulder pain
Study: NCT04916353
Drug: Triamcinolone Acetonide.
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone Acetonide 40mg/1ml injection
Study: NCT00189800
Drug: Solifenacin succinate
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00044837
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06598527
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-L1 inhibitor
Study: NCT06096857
Drug: Roseomonas mucosa (RSM2015) and Cardamom seeds
Normalized name: Cardamom
DrugBank: Cardamom (DB16576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze dried packet to be reconstituted in water
Study: NCT06435702
Drug: Darolutamide in addition to androgen deprivation therapy
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darolutamide 600mg twice daily. The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration
Study: NCT05014139
Drug: Enfortumab vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given into the bladder (intravesically)
Study: NCT06788197
Drug: SHR-A1811+ Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SHR-A1811 is administered intravenously; fulvestrant is administered Intramuscular
Study: NCT06788197
Drug: SHR-A1811+ Fulvestrant+HS-10352
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SHR-A1811 is administered intravenously; fulvestrant is administered Intramuscular ； HS-10351 is administered orally
Study: NCT04736199
Drug: Darolutamide (Nubeqa, BAY1841788)
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Coated tablet, oral administration
Study: NCT06347016
Drug: Plozasiran Injection
Normalized name: Plozasiran
DrugBank: Plozasiran (DB18997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARO-APOC3 Injection
Study: NCT06512194
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The psilocybin is produced under Good Manufacturing Practice and is in a capsule that contains 25 mg of synthetic psilocybin.
Study: NCT06461897
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Tablet or Oral Solution
Study: NCT06461897
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous Injection
Study: NCT06246643
Drug: Regorafenib (Stivarga, BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be treated with the regorafenib dose taken during the last cycle of the feeder study. Adult participants will receive either 60, 80, 90, 120, or 160 mg orally (p.o.) once daily (qd) for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off). Pediatric participants will receive 82 mg/m\^2 p.o. qd for 14 days, in a 14 days on/7 days off schedule (21-day cycle).
Study: NCT05582395
Drug: Mavacamten
Normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06131983
Drug: ARO-DUX4 for Injection
Normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single or multiple doses of ARO-DUX4 by intravenous (IV) infusion
Study: NCT05357482
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized 4-12 weeks prior to planned transplant date
Study: NCT05357482
Drug: Filgrastim (G-CSF)
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: May be used to minimize the days of neutropenia, and may be administered beginning near day 10 post stem cell infusion at 5 mcg/kg (rounding to the nearest vial) at the discretion of investigator.
Study: NCT05357482
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For immune suppression (day -1)
Study: NCT05357482
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For autologous HSC collection; dose of plerixafor at 240 mcg/kg (capped at 20mg)
Study: NCT06643728
Drug: Bimagrumab
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06643728
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06643728
Drug: Bimagrumab Placebo
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06643728
Drug: Tirzepatide Placebo
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06517875
Drug: Momelotinib
Normalized name: MOMELOTINIB
DrugBank: Momelotinib (DB11763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momelotinib will be administered orally.
Study: NCT06517875
Drug: Luspatercept
Normalized name: Luspatercept
DrugBank: Luspatercept (DB12281)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Luspatercept will be administered subcutaneously.
Study: NCT04821375
Drug: bazedoxifene plus conjugated estrogens
Normalized name: bazedoxifene / estrogens, conjugated (USP)
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.
Study: NCT06486844
Drug: Vericiguat (Verquvo, BAY1021189)
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vericiguat was given following routine clinical practice.
Study: NCT06617429
Drug: GTX-102
Normalized name: GTX-102
DrugBank: GTX-102 (DB16981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: antisense oligonucleotide
Study: NCT05083364
Drug: ARO-C3
Normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARO-C3 for sc injection
Study: NCT04824911
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300mg loading and 75mg/day from day 2
Study: NCT04824911
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin(100-300mg/day)
Study: NCT04824911
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 40-80mg/day
Study: NCT04760769
Drug: Tavapadon
Normalized name: Tavapadon
DrugBank: Tavapadon (DB14899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Tavapadon at a dose of (5 to 15) mg QD, orally during a 58-week treatment period.
Study: NCT05300477
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbonic Anhydrase Inhibitor
Study: NCT05300477
Drug: Erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone for red blood cell
Study: NCT04586504
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/mL concentration of midazolam. Maximum dose = 10 mg. Administered using a mucosal atomization device.
Study: NCT06406400
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Healthy participants will receive itraconazole orally from Days 6 to 8 in Period 2 and Days 9 to 21 in Period 3.
Study: NCT06406400
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants with OUD will receive buprenorphine (as standard of care treatment) on Day 4.
Study: NCT06406400
Drug: Buprenorphine / Naloxone
Normalized name: buprenorphine / naloxone
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants with OUD will receive buprenorphine + naloxone (as standard of care treatment) on Days 4, 5, 6 and 7
Study: NCT06406400
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants with OUD will receive hydromorphone (as a replacement opioid) on Days 1, 2 and 3.
Study: NCT05579132
Drug: CN201
Normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatments include 2 cycles of induction treatment, 3 cycles of consolidation treatment, and up to 7 cycles of maintenance treatment. During the Treatment Period, subjects will receive CN201 by intravenous (IV) infusion once every week (QW), 4 weeks per treatment cycle. The subjects will receive 2 cycles of CN201 for induction. After induction treatment, the drug is discontinued for 2 weeks (treatment-free interval) before consolidation therapy is started, and each subsequent treatment cycle (4 weeks/treatment cycle) is followed by a 2-week treatment-free interval. Responders to induction treatment will continue to receive 3 cycles of consolidation treatment, followed by an additional up to 7 cycles of maintenance treatment, or until intolerable toxicity, disease progression, withdrawal of informed consent, loss to follow-up, receipt of other antitumor therapy, or death, whichever occurs first.
Study: NCT05726032
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.
Study: NCT06646276
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06646276
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05014646
Drug: Cholestyramine
Normalized name: Cholestyramine
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05014646
Drug: Leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04283656
Drug: Doravirine/Lamivudine/Tenofovir
Normalized name: doravirine/lamivudine/tenofovir
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg/300mg/300mg orally for one dose, daily
Study: NCT03943901
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab is a monoclonal antibody
Study: NCT03943901
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy drug, plant alkaloid
Study: NCT03943901
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroid, anti-inflammatory
Study: NCT05279040
Drug: Trikafta
Normalized name: Trikafta
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Elexacaftor/Tezacaftor/Ivacaftor combination therapy
Study: NCT05467748
Drug: Tulmimetostat
Normalized name: Tulmimetostat
DrugBank: Tulmimetostat (DB19446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of oral tazemetostat and intravenous pembrolizumab treatment for patients with advanced non-small cell lung cancer
Study: NCT05001984
Drug: Alirocumab
Normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Alirocumab 75mg subcutaneously every 2 weeks for a total of 26 weeks.
Study: NCT04762992
Drug: subcutaneous Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin subcutaneous injections (40 mg, 4000 IU daily) starting immediately after the diagnosis of FGR, and until 36 weeks of gestation or 12 hours before delivery, whichever comes first.
Study: NCT06550076
Drug: TAK-279
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-279 oral tablet
Study: NCT04602598
Drug: Zanubrutinib 80 MG
Normalized name: zanubrutinib 80 MG
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 80 MG for 24 weeks
Study: NCT05371093
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05371093
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT05371093
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT05371093
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05371093
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05371093
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT06080893
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FCM can be administered in a short IV infusion of 15-20 minutes, allowing doses of 2 g in a single session, and furthermore, FCM is excellently tolerated and safe for patients.~FCM will be administered intravenously at preop 24th hour according to weight and preop hgb level
Study: NCT06145282
Drug: Non-myeloablative haploidentical peripheral blood stem cell transplantation with briquilimab and abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All participants will receive the same dose of the investigational briquilimab antibody and abatacept added to the NIH-established regimen of alemtuzumab-TBI-sirolimus and infusion of filgrastim-mobilized peripheral blood hematopoietic cells from haploidentical related donors.
Study: NCT05208944
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: programmed cell death protein 1 (PD-1) inhibitor
Study: NCT06176794
Drug: Immediate release torsemide 20mg tablet
Normalized name: Torsemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 20mg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.
Study: NCT06176794
Drug: Extended release torsemide 24mg tablet
Normalized name: Torsemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 20mg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.
Study: NCT06290934
Drug: GS-1427
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT05242315
Drug: Prograf (SOC)
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prograf (SOC)
Study: NCT04671836
Drug: Lorazepam 1Mg Tablet
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg, white, five-sided (shield shape) tablet with a raised A on one side and BPI and 64 impressed on scored reverse side. NDC 0187-0064-01 - Bottles of 100 tablets; NDC 0187-0064-50 - Bottles of 500 tablets; NDC 0187-0064-10 - Bottles of 1000 tablets.~The pharmacy at the Zucker Hillside Hospital will encapsulate both lorazepam 1 mg and placebo pills to make them look the same. On the day of the scan, the research coordinator or the PI will pick up the blinded study medication (lorazepam or placebo) and will administer it to the participant. One hour later, the participant will be placed in the scanner to complete the MRI.